-
Mashup Score: 1
First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker. According to findings from a joint survey conducted by the American Thyroid Association and European Thyroid Association (ETA), providers had different opinions on first-line therapy for
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2
First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker. According to findings from a joint survey conducted by the American Thyroid Association and European Thyroid Association (ETA), providers had different opinions on first-line therapy for
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Moderate/severe #thyroid eye disease is being treated differently in Europe and North America, with most North American providers opting to prescribe teprotumumab and most European clinicians prescribing IV steroids. @doctorjuanpa ]#ATA2021 @AmThyroidAssn https://t.co/G4EoZjIuco
-
Moderate/severe #thyroid eye disease is being treated differently in Europe and North America, with most North American providers opting to prescribe teprotumumab and most European clinicians prescribing IV steroids. @doctorjuanpa ]#ATA2021 @AmThyroidAssn https://t.co/1xP8UxEvPI
-
-
Mashup Score: 0
Young adults who received radioactive iodine therapy for differentiated thyroid cancer were at 92% increased risk for leukemia and 23% increased risk for any solid malignancies vs. those who did not receive radioactive iodine therapy.Among solid cancers, researchers observed elevated risk for uterine, breast, lung and salivary gland cancers; solid malignancy risks increased with greater time
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “Future research should determine whether the risks of second cancers after radioactive iodine therapy are dose-dependent." #thyroid #ATA2021 @AmThyroidAssn https://t.co/ae3isEbrj2
-
-
Mashup Score: 1
Young adults who received radioactive iodine therapy for differentiated thyroid cancer were at 92% increased risk for leukemia and 23% increased risk for any solid malignancies vs. those who did not receive radioactive iodine therapy.Among solid cancers, researchers observed elevated risk for uterine, breast, lung and salivary gland cancers; solid malignancy risks increased with greater time
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “Our results reinforce the notion that treatment decisions regarding the use of radioactive iodine therapy should consider the balance of risks and benefits for individual patients with differentiated #thyroid cancer." #ATA2021 @AmThyroidAssn https://t.co/ae3isEbrj2
-
-
Mashup Score: 0
Young adults who received radioactive iodine therapy for differentiated thyroid cancer were at 92% increased risk for leukemia and 23% increased risk for any solid malignancies vs. those who did not receive radioactive iodine therapy.Among solid cancers, researchers observed elevated risk for uterine, breast, lung and salivary gland cancers; solid malignancy risks increased with greater time
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Young adults who received radioactive iodine therapy to treat differentiated #thyroid cancer had a higher risk for other cancers later in life, according to two presenters at #ATA2021. @AmThyroidAssn https://t.co/OlKVx5I6sH
-
Young adults who received radioactive iodine therapy to treat differentiated #thyroid cancer had a higher risk for other cancers later in life, according to two presenters at #ATA2021. @AmThyroidAssn https://t.co/ae3isEbrj2
-
-
Mashup Score: 0Year in review: Five studies changing thyroidology practice - 3 year(s) ago
In an update on notable, recently conducted thyroid studies, a speaker reviewed the latest treatments and imaging modalities for children and adults that have the potential to change thyroidology practice. “As a clinician-researcher, I focused on studies that are novel and potentially practice-changing,” Megan R. Haymart, MD, professor of medicine, metabolism, endocrinology and
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “When you think about risk vs. benefits (for teprotumumab), there was an excellent response, and most adverse events were grade 1 or 2. This is another therapeutic option, and it may change clinical practice.” #thyroid #ATA2021 @AmThyroidAssn https://t.co/P7YFeCVh3A
-
-
Mashup Score: 0Year in review: Five studies changing thyroidology practice - 3 year(s) ago
In an update on notable, recently conducted thyroid studies, a speaker reviewed the latest treatments and imaging modalities for children and adults that have the potential to change thyroidology practice. “As a clinician-researcher, I focused on studies that are novel and potentially practice-changing,” Megan R. Haymart, MD, professor of medicine, metabolism, endocrinology and
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: "Two of the publications focus on new or more tailored treatment options for select patients, and three of the publications challenge current practice paradigms and/or suggest a need for new research directions.” #thyroid #ATA2021 @AmThyroidAssn https://t.co/P7YFeCVh3A
-
-
Mashup Score: 1Year in review: Five studies changing thyroidology practice - 3 year(s) ago
In an update on notable, recently conducted thyroid studies, a speaker reviewed the latest treatments and imaging modalities for children and adults that have the potential to change thyroidology practice. “As a clinician-researcher, I focused on studies that are novel and potentially practice-changing,” Megan R. Haymart, MD, professor of medicine, metabolism, endocrinology and
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
In a year-end clinical thyroidology update presented at #ATA2021, Megan Haymart, MD, highlighted five potentially practice-changing studies on treatments for #MTC, #TED, thyroid disease in pregnancy and more. @AmThyroidAssn https://t.co/dAAZHhX6VC
-
-
Mashup Score: 5
ATA2021 is brought to you by ATA As the only organization completely focused on advancing telehealth, ATA is working to change the way the world thinks about healthcare. We are committed to ensuring that everyone has access to safe, effective, and appropriate care when and where they need it, and that providers can do more good for more people. We represent a broad and inclusive member network of…
Source: ATA 2021 Annual ConferenceCategories: Healthcare Professionals, Latest HeadlinesTweet-
It was great to be on a panel of women talking about #healthcare and #tech at this year's #ATA2021. #DigitalTransformation in healthcare is reimagining patient access. Watch @AmericanTelemed's replay ▶️ https://t.co/sDJqivEQwn @TamiErwinVZ @MujadalaEsq
-
-
Mashup Score: 1
From interoperability to consumer expectations, experts at the annual conference share their outlook on the virtual care landscape.
Categories: Healthcare Professionals, Latest HeadlinesTweet-
Our #ATA2021 panel explained "MeCare," highly personalized healthcare in emerging #omnichannel health/care ecosystem https://t.co/pmHjOizhFc TY @CDW_Healthcare journal @HealthTechMag for covering our session in this #digitaltransformation article @AmericanTelemed #HeartHealth https://t.co/1LH6Q7FYLy
-
ICYMI: “Teprotumumab has become the treatment of choice in North America for moderate active #thyroid eye disease. IV steroids continue to be the treatment of choice in Europe and other regions." @doctorjuanpa #ATA2021 @AmThyroidAssn https://t.co/1xP8UxEvPI